Viewing Study NCT00237445



Ignite Creation Date: 2024-05-05 @ 12:04 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00237445
Status: TERMINATED
Last Update Posted: 2011-01-11
First Post: 2005-10-10

Brief Title: Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia CAP Treated With Either Telithromycin Once Daily for 7 Days or Azithromycin Once Daily for 5 Days
Sponsor: Sanofi
Organization: Sanofi

Study Overview

Official Title: A Multinational Multicenter Randomized Double-blind Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia CAP Treated With Either Ketek Telithromycin Once Daily for 7 Days or Zithromax Azithromycin Once Daily for 5 Days
Status: TERMINATED
Status Verified Date: 2011-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: COBRA II
Brief Summary: A multinational multicenter randomized double-blind study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia CAP treated with either telithromycin once daily for 7 days or azithromycin once daily for 5 days
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None